ID   H1975 BIR
AC   CVCL_E4DI
SY   H1975BIR
RX   PubMed=39061985;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_232716; (20R)-10,15,20-trimethyl-2-[(4-methylpiperazin-1-yl)methyl]-18,19,20,21-tetrahydro-15H,17H-12,8-(metheno)pyrazolo[3',4':2,3][1,5,10,12]oxatriazacycloheptadecino[12,11-a]benzimidazol-7(6H)-one (BI-4020).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Gly118Asp (c.353G>A); ClinVar=VCV000156446; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1511 ! NCI-H1975
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 19-12-24; Last updated: 19-12-24; Version: 1
//
RX   PubMed=39061985; DOI=10.3390/biomedicines12071412; PMCID=PMC11273927;
RA   Fukuda S., Suda K., Hamada A., Oiki H., Ohara S., Ito M., Soh J.,
RA   Mitsudomi T., Tsutani Y.;
RT   "Potential utility of a 4th-generation EGFR-TKI and exploration of
RT   resistance mechanisms -- an in vitro study.";
RL   Biomedicines 12:1412.1-1412.13(2024).
//